AAAAAA

   
Results: 1-25 | 26-29
Results: 1-25/29
RANDOMIZED PHASE-II TRIAL OF INFUSIONAL FLUOROURACIL, EPIRUBICIN, ANDCYCLOPHOSPHAMIDE VERSUS INFUSIONAL FLUOROURACIL, EPIRUBICIN, AND CISPLATIN IN PATIENTS WITH ADVANCED BREAST-CANCER
Authors: EISEN T SMITH IE JOHNSTON S ELLIS PA PRENDIVILLE J SEYMOUR MT WALSH G ASHLEY S
Citation: T. Eisen et al., RANDOMIZED PHASE-II TRIAL OF INFUSIONAL FLUOROURACIL, EPIRUBICIN, ANDCYCLOPHOSPHAMIDE VERSUS INFUSIONAL FLUOROURACIL, EPIRUBICIN, AND CISPLATIN IN PATIENTS WITH ADVANCED BREAST-CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1350-1357
EXCHANGE OF VIRAL PROMOTER ENHANCER ELEMENTS WITH HETEROLOGOUS REGULATORY SEQUENCES GENERATES TARGETED HYBRID LONG TERMINAL REPEAT VECTORS FOR GENE-THERAPY OF MELANOMA/
Authors: DIAZ RM EISEN T HART IR VILE RG
Citation: Rm. Diaz et al., EXCHANGE OF VIRAL PROMOTER ENHANCER ELEMENTS WITH HETEROLOGOUS REGULATORY SEQUENCES GENERATES TARGETED HYBRID LONG TERMINAL REPEAT VECTORS FOR GENE-THERAPY OF MELANOMA/, Journal of virology, 72(1), 1998, pp. 789-795
EARLY IDENTIFICATION OF PATIENTS AT RISK OF DEATH DUE TO INFECTIONS, HEMORRHAGE, OR GRAFT FAILURE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION ON THE BASIS OF THE LEUKOCYTE COUNTS
Authors: MEHTA J POWLES R SINGHAL S HORTON C MIDDLETON G EISEN T MELLER S PINKERTON CR TRELEAVEN J
Citation: J. Mehta et al., EARLY IDENTIFICATION OF PATIENTS AT RISK OF DEATH DUE TO INFECTIONS, HEMORRHAGE, OR GRAFT FAILURE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION ON THE BASIS OF THE LEUKOCYTE COUNTS, Bone marrow transplantation, 19(4), 1997, pp. 349-355
NOVEL VACCINE TECHNOLOGIES
Authors: EISEN T
Citation: T. Eisen, NOVEL VACCINE TECHNOLOGIES, Trends in biotechnology, 15(12), 1997, pp. 483-484
COMPARISON OF MARROW VS BLOOD-DERIVED STEM-CELLS FOR AUTOGRAFTING IN PREVIOUSLY UNTREATED MULTIPLE-MYELOMA
Authors: RAJE N POWLES R HORTON C MILLAR B SHEPHERD V MIDDLETON G KULKARNI S EISEN T MEHTA J SINGHAL S TRELEAVEN J
Citation: N. Raje et al., COMPARISON OF MARROW VS BLOOD-DERIVED STEM-CELLS FOR AUTOGRAFTING IN PREVIOUSLY UNTREATED MULTIPLE-MYELOMA, British Journal of Cancer, 75(11), 1997, pp. 1684-1689
LONG-TERM FOLLOW-UP OF PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOID-LEUKEMIA IN FIRST COMPLETE REMISSION AFTER CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION AND CYCLOSPORINE
Authors: MEHTA J POWLES R TRELEAVEN J HORTON C TAIT D MELLER S PINKERTON CR MIDDLETON G EISEN T SINGHAL S
Citation: J. Mehta et al., LONG-TERM FOLLOW-UP OF PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOID-LEUKEMIA IN FIRST COMPLETE REMISSION AFTER CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION AND CYCLOSPORINE, Bone marrow transplantation, 18(4), 1996, pp. 741-746
FACTORS AFFECTING ENGRAFTMENT AFTER UNPURGED AUTOGRAFTING IN ACUTE-LEUKEMIA
Authors: MIDDLETON G POWLES R SINGHAL S EISEN T TRELEAVEN J MEHTA J
Citation: G. Middleton et al., FACTORS AFFECTING ENGRAFTMENT AFTER UNPURGED AUTOGRAFTING IN ACUTE-LEUKEMIA, British Journal of Haematology, 93, 1996, pp. 168-168
IDARUBICIN HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTIONIN PATIENTS WITH RELAPSED ACUTE-LEUKEMIA
Authors: EISEN T POWLES R SINGHAL S MIDDLETON G TRELEAVEN J MEHTA J
Citation: T. Eisen et al., IDARUBICIN HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTIONIN PATIENTS WITH RELAPSED ACUTE-LEUKEMIA, British Journal of Haematology, 93, 1996, pp. 253-253
LONG-TERM FOLLOW-UP OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOID-LEUKEMIA IN FIRST REMISSION AFTER CYCLOPHOSPHAMIDE TOTAL-BODY IRRADIATION AND CYCLOSPORINE
Authors: EISEN T POWLES R SINGHAL S MIDDLETON G TRELEAVEN J MEHTA J
Citation: T. Eisen et al., LONG-TERM FOLLOW-UP OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOID-LEUKEMIA IN FIRST REMISSION AFTER CYCLOPHOSPHAMIDE TOTAL-BODY IRRADIATION AND CYCLOSPORINE, British Journal of Haematology, 93, 1996, pp. 257-257
SALVAGE TREATMENT WITH VAMP C-VAMP INFUSIONAL CHEMOTHERAPY AND HIGH-DOSE MELPHALAN IN REFRACTORY MYELOMAS
Authors: RAJE N POWLES R HORTON CAP MILAN S MIDDLETON G EISEN T VINER C TRELEAVEN J CUNNINGHAM D
Citation: N. Raje et al., SALVAGE TREATMENT WITH VAMP C-VAMP INFUSIONAL CHEMOTHERAPY AND HIGH-DOSE MELPHALAN IN REFRACTORY MYELOMAS, British Journal of Haematology, 93, 1996, pp. 303-303
AUTOGRAFTING IN MYELOMA PATIENTS WITH RENAL IMPAIRMENT
Authors: RAJE N POWLES R MILAN S MIDDLETON G EISEN T MEHTA J SINGHAL S TRELEAVEN J
Citation: N. Raje et al., AUTOGRAFTING IN MYELOMA PATIENTS WITH RENAL IMPAIRMENT, British Journal of Haematology, 93, 1996, pp. 304-304
A RANDOMIZED TRIAL OF SHORT-COURSE CONSOLIDATION CHEMOTHERAPY FOLLOWING HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA
Authors: RAJE N POWLES R EISEN T MIDDLETON G FIELD M MEHTA J SINGHAL S TRELEAVEN J MILAN S
Citation: N. Raje et al., A RANDOMIZED TRIAL OF SHORT-COURSE CONSOLIDATION CHEMOTHERAPY FOLLOWING HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA, British Journal of Haematology, 93, 1996, pp. 305-305
EFFECT OF KARYOTYPE ABNORMALITIES (INCLUDING FAILURE TO OBTAIN METAPHASES) ON RESPONSE TO INDUCTION CHEMOTHERAPY AND SURVIVAL IN ACUTE MYELOID-LEUKEMIA
Authors: POWLES R SINGHAL S TRELEAVEN J SWANSBURY GJ MIN T HORTON C MIDDLETON G EISEN T CATOVSKY D MEHTA J
Citation: R. Powles et al., EFFECT OF KARYOTYPE ABNORMALITIES (INCLUDING FAILURE TO OBTAIN METAPHASES) ON RESPONSE TO INDUCTION CHEMOTHERAPY AND SURVIVAL IN ACUTE MYELOID-LEUKEMIA, Blood, 88(10), 1996, pp. 3364-3364
HIGH-DOSE CYTARABINE AND VP-16 WITH OR WITHOUT IDARUBICIN FOR RELAPSED ACUTE-LEUKEMIA
Authors: KULKARNI S POWLES R EISEN T TRELEAVEN J SINGHAL S MIDDLETON G HORTON C MEHTA J
Citation: S. Kulkarni et al., HIGH-DOSE CYTARABINE AND VP-16 WITH OR WITHOUT IDARUBICIN FOR RELAPSED ACUTE-LEUKEMIA, Blood, 88(10), 1996, pp. 3423-3423
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - IMPORTANCE OF INFECTION PROPHYLAXIS
Authors: MEHTA J POWLES R SINGHAL S RILEY U SASO R WILSON K EISEN T MIDDLETON G TRELEAVEN J CATOVSKY D
Citation: J. Mehta et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - IMPORTANCE OF INFECTION PROPHYLAXIS, Blood, 88(10), 1996, pp. 3781-3781
HEMATOPOIESIS IN ACUTE MYELOID-LEUKEMIA PATIENTS IN LONG-TERM REMISSION AND AT RELAPSE - INFLUENCE OF PREVIOUS THERAPY
Authors: POWLES R TRELEAVEN J SINGHAL S KULKARNI S HORTON C MIDDLETON G EISEN T MEHTA J
Citation: R. Powles et al., HEMATOPOIESIS IN ACUTE MYELOID-LEUKEMIA PATIENTS IN LONG-TERM REMISSION AND AT RELAPSE - INFLUENCE OF PREVIOUS THERAPY, Blood, 88(10), 1996, pp. 3807-3807
THE FEASIBILITY OF SHORT-COURSE CONSOLIDATION CHEMOTHERAPY FOLLOWING HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA
Authors: POWLES R RAJE N KULKARNI S EISEN T MIDDLETON G FIELD M MEHTA J SINGHAL S TRELEAVEN J MILAN S
Citation: R. Powles et al., THE FEASIBILITY OF SHORT-COURSE CONSOLIDATION CHEMOTHERAPY FOLLOWING HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA, Blood, 88(10), 1996, pp. 3871-3871
AUTOGRAFTING IN MYELOMA PATIENTS WITH RENAL IMPAIRMENT
Authors: RAJE N POWLES R KULKARNI S MILAN S MIDDLETON G EISEN T TRELEAVEN J
Citation: N. Raje et al., AUTOGRAFTING IN MYELOMA PATIENTS WITH RENAL IMPAIRMENT, Blood, 88(10), 1996, pp. 3872-3872
PREDICTORS OF EARLY RELAPSE FOLLOWING AUTOGRAFTING FOR MYELOMA
Authors: RAJE N POWLES R HORTON C KULKARNI S EISEN T MIDDLETON G TRELEAVEN J
Citation: N. Raje et al., PREDICTORS OF EARLY RELAPSE FOLLOWING AUTOGRAFTING FOR MYELOMA, Blood, 88(10), 1996, pp. 510-510
INDUCTION OF GRAFT-VERSUS-HOST DISEASE AS IMMUNOTHERAPY OF LEUKEMIA RELAPSING AFTER ALLOGRAFTING - SINGLE-CENTER EXPERIENCE OF 28 ADULTS
Authors: MEHTA J POWLES R SINGHAL S MIDDLETON G EISEN T SASO R KULKARNI S WILSON K BENJAMIN A DENT J ALTON P KILLICK S GRAVETT P TRELEAVEN J
Citation: J. Mehta et al., INDUCTION OF GRAFT-VERSUS-HOST DISEASE AS IMMUNOTHERAPY OF LEUKEMIA RELAPSING AFTER ALLOGRAFTING - SINGLE-CENTER EXPERIENCE OF 28 ADULTS, Blood, 88(10), 1996, pp. 1028-1028
BONE-MARROW TRANSPLANTATION FROM HLA-MISMATCHED FAMILY DONORS FOR ACUTE MYELOID-LEUKEMIA - 10-YEAR FOLLOW-UP
Authors: MIDDLETON G POWLES R SINGHAL S HORTON C KULKARNI S EISEN T DENT J TRELEAVEN J MEHTA J
Citation: G. Middleton et al., BONE-MARROW TRANSPLANTATION FROM HLA-MISMATCHED FAMILY DONORS FOR ACUTE MYELOID-LEUKEMIA - 10-YEAR FOLLOW-UP, Blood, 88(10), 1996, pp. 1064-1064
THALIDOMIDE FOR ACUTE OR CHRONIC GRAFT-VERSUS-HOST DISEASE
Authors: KULKARNI S POWLES R MEHTA J HORTON C TRELEAVEN J MIDDLETON G EISEN T SINGHAL S
Citation: S. Kulkarni et al., THALIDOMIDE FOR ACUTE OR CHRONIC GRAFT-VERSUS-HOST DISEASE, Blood, 88(10), 1996, pp. 2424-2424
EARLY LYMPHOCYTE RECOVERY AFTER ALLOGRAFTING FOR ACUTE MYELOID-LEUKEMIA AND RISK OF RELAPSE - IDENTIFICATION OF PATIENTS WHO MAY BENEFIT FROM PROPHYLACTIC IMMUNOTHERAPY
Authors: POWLES R TRELEAVEN J SINGHAL S KULKARNI S HORTON C MIDDLETON G EISEN T MEHTA J
Citation: R. Powles et al., EARLY LYMPHOCYTE RECOVERY AFTER ALLOGRAFTING FOR ACUTE MYELOID-LEUKEMIA AND RISK OF RELAPSE - IDENTIFICATION OF PATIENTS WHO MAY BENEFIT FROM PROPHYLACTIC IMMUNOTHERAPY, Blood, 88(10), 1996, pp. 2711-2711
THE POU DOMAIN TRANSCRIPTION FACTOR BRN-2 - ELEVATED EXPRESSION IN MALIGNANT-MELANOMA AND REGULATION OF MELANOCYTE-SPECIFIC GENE-EXPRESSION
Authors: EISEN T EASTY DJ BENNETT DC GODING CR
Citation: T. Eisen et al., THE POU DOMAIN TRANSCRIPTION FACTOR BRN-2 - ELEVATED EXPRESSION IN MALIGNANT-MELANOMA AND REGULATION OF MELANOCYTE-SPECIFIC GENE-EXPRESSION, Oncogene, 11(10), 1995, pp. 2157-2164
SMALL-CELL LUNG-CANCER - DISCUSSION
Authors: EISEN T HICKISH T SLOANE J ECCLES S SMITH IE
Citation: T. Eisen et al., SMALL-CELL LUNG-CANCER - DISCUSSION, Lancet, 345(8960), 1995, pp. 1285-1289
Risultati: 1-25 | 26-29